Status:
UNKNOWN
To Explore the Safety and Efficacy of Intravenous Infusion of Different Doses of Lidocaine in Patients
Lead Sponsor:
West China Hospital
Conditions:
Liver Cancer
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
All patients who met the inclusion criteria were randomly divided into four groups, 30 cases in each group, which were lidocaine group 1, lidocaine group 1.5, lidocaine group 2, and the placebo group ...
Detailed Description
All patients who met the inclusion criteria were randomly divided into four groups, 30 cases in each group, which were lidocaine group 1, lidocaine group 1.5, lidocaine group 2, and the placebo group ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Age: 18-70 years old
- American Society of Anesthesiologists(ASA) Ⅰ～III
- BMI≤30
- Intended for open liver resection Exclusion criteria：1. Long-term opioid users 2. Patients with contraindications or allergies to any drugs (lidocaine, etc.) used in this study 3. Patients with severe hepatic insufficiency before surgery (defined as total bilirubin\>1.46mg/dl), renal insufficiency (glomerular filtration rate \<30ml/min/1.73m2 or end-stage renal disease) 4. Associated with severe heart disease (second or third degree atrioventricular block); severe heart failure (ejection fraction \<50%); sinus bradycardia; patient 6. Patients who participated in other clinical trials within 3 months before enrollment in the study.
Exclusion
Key Trial Info
Start Date :
July 27 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 27 2022
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT05369650
Start Date
July 27 2019
End Date
September 27 2022
Last Update
May 11 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
West China Hospital
Chengdu, Sichuan, China, 610041